文献速递胸部肿瘤

BRAF-V600突变非小细胞肺癌的治疗顺序:一线靶向治疗对比一线(化疗)免疫治疗

Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy.
PubMed 文献 · J Thorac Oncol · 2025-05-08

这项回顾性研究纳入德国国家基因组医学肺癌网络205例转移性BRAF-V600突变NSCLC患者,175例接受一线治疗。一线达拉非尼/曲美替尼与化疗/免疫治疗的OS相似(中位28.0个月 vs 27.8个月,HR 1.1,p=0.68)。女性OS优于男性,高PD-L1状态与一线治疗失败时间缩短相关。

要点

  • 一线DAB/TRM与化疗/IO的OS相似(中位28.0个月 vs 27.8个月,HR 1.1,p=0.68)。
  • 女性OS优于男性(HR 0.65,p=0.049),主要源于一线DAB/TRM组(OS HR 0.53,p=0.015)。
  • 高PD-L1(TPS≥50%)与一线治疗失败时间缩短相关(HR 1.83,p=0.002)。

核心结论

  • BRAF-V600突变NSCLC一线靶向治疗或免疫为基础的治疗具有相似的生存结局。
  • 性别和PD-L1状态可能有助于个体化决策。

研究设计与样本

  • 回顾性研究,纳入德国国家基因组医学肺癌网络诊断为转移性BRAF-V600突变NSCLC的患者。
  • 共识别205例患者,其中175例接受一线治疗:达拉非尼/曲美替尼(DAB/TRM)65.1%,单药免疫治疗19.4%,化疗-免疫治疗15.4%。

主要发现

  • 一线DAB/TRM组中位OS为28.0个月,化疗/IO组为27.8个月(HR 1.1,p=0.68)。
  • 女性OS优于男性(HR 0.65,p=0.049,多因素模型证实),主要源于一线DAB/TRM组女性OS优于男性(OS HR 0.53,p=0.015)。
  • 接受免疫为基础一线治疗的患者中无性别生存差异(OS HR 1.02)。
  • 高PD-L1状态(肿瘤比例评分≥50%)与一线治疗失败时间缩短相关(HR 1.83,p=0.002,调整性别后多因素模型证实),无论一线方案为免疫为基础还是靶向治疗;OS呈非显著趋势(HR 1.4)。

关键数值与推荐

  • 一线DAB/TRM中位OS 28.0个月 vs 化疗/IO 27.8个月(HR 1.1,p=0.68)。
  • 女性OS HR 0.65(p=0.049);一线DAB/TRM组女性OS HR 0.53(p=0.015)。
  • 免疫为基础一线治疗组性别OS HR 1.02。
  • PD-L1 TPS≥50%与一线治疗失败时间缩短相关(HR 1.83,p=0.002);OS HR 1.4(非显著趋势)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Targeted treatment of patients with metastatic BRAF-V600-mutated NSCLC using BRAF/MEK-inhibitors is effective but limited by acquired resistance. Patients with BRAF-mutant NSCLC may derive long-lasting benefit from immune checkpoint inhibition with programmed death-1/programmed death-ligand 1 (PD-L1) antibodies (immuno-oncology [IO]). Although IO is the preferred first-line therapy in BRAF-mutated melanoma, the optimal treatment sequence in BRAF-mutated NSCLC is not defined. METHODS: This retrospective study investigated the clinical outcome of patients with metastatic BRAF-V600-mutated NSCLC diagnosed in the German national Network Genomic Medicine Lung Cancer. RESULTS: We identified 205 patients with BRAF-V600-mutated NSCLC; 175 patients received first-line therapy with dabrafenib/trametinib (DAB/TRM, 65.1%), IO alone (19.4%), or chemotherapy-IO (15.4%). Overall survival (OS) and time-to-treatment failure of first-line therapy was identical for patients receiving first-line DAB/TRM (median OS 28.0 months) or chemo/IO (27.8 months, hazard ratio [HR] 1.1, p = 0.68). Female patients had superior OS (HR 0.65, p = 0.049, confirmed in multivariate model), which was mainly driven by superior OS of female to that of male patients receiving first-line DAB/TRM (OS HR 0.53, p = 0.015). There was no sex difference in survival of patients receiving IO-based first-line treatment (OS HR 1.02). Surprisingly, high PD-L1 status (tumor proportion score ≥50%) was associated with shortened time-to-treatment failure in first-line treatment (HR 1.83, p = 0.002, confirmed in multivariate models adjusting for sex; OS with nonsignificant trend, HR 1.4), regardless of whether the first-line regimen was IO-based or targeted therapy. CONCLUSIONS: Targeted or IO-based first-line treatment of BRAF-V600-mutated NSCLC has similar survival outcomes. Sex and PD-L1 status may support decision-making at the individual patient level.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Wiesweg M, Alaffas A, Rasokat A, et al. Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy. J Thorac Oncol. 2025. PMID: 40345491. doi:10.1016/j.jtho.2025.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。